Dr.

Reddys
at a glance
Our purpose
We accelerate
access to
affordable and
innovative
medicines
because

Dr. Reddys at a glance 7/6/2017 2

Content
1. Who we are
2. Our journey so far
3. An exciting future
Section 1

Who we are

I want to build a company thatd last 500 years.

- Dr. K Anji Reddy, Founder Chairman
We are a global pharmaceutical
company with three key businesses

Pharmaceutical Global Generics Proprietary

Services & Active Products
Ingredients

Partner of Choice Access to affordable medicines Fulfilling unmet medical needs

in dermatology & neurology

A leader in generic API

supply globally
Finished dosages in distribution- Building sustainable and
profitable proprietary
and detailing-driven markets
products
Customers are generics
Key markets: America, India,
manufacturers and
innovator firms
Russia Strong pipeline of
differentiated formulations

Building a sustainable
biosimilars business

Dr. Reddys at a glance 7/6/2017 5

We are present in all major regions of the world
Commercial
presence in

31
countries

France Italy Spain Switzerland Columbia

Malaysia

4 80
25 Global
20k+ Countries 40
Global benefit from
R&D Associates Nationalities
Plants our
Centres medicines
7/6/2017 6
We use science and technology to provide affordable
and innovative medicines

Industry-leading chemistry skills

First Indian-company-
Niche product opportunities (Tacrolimus,
launched Para IV product,
Metoprolol succinate, Azacitadine, Divalproex Fluoxetine, in USA
Sodium ER)

Vertical integration
Worlds first generic
Integrated R&D monoclonal antibody of
API manufacturing (10 facilities) Rituximab Reditux
Formulations manufacturing (15 facilities)

Early-mover advantage in biosimilars Several complex generics

launched in USA with fewer
4 biosimilar products being marketed than three competitors, e.g.,
Fondaparinux
Biologics development and manufacturing in India

Dr. Reddys at a glance 7/6/2017 7

Our purpose guides our customer value proposition
and strategic choices

Purpose

We accelerate access to affordable and innovative medicines because Good Health Cant Wait.

Customer value proposition

Bring expensive Address unmet Help patients Equip partners to Ensure products are
Medicines within patients needs manage disease succeed always on the shelf
reach better

Strategic choices

Offer our patients the products they value most and help our partners succeed through our flexible supply chain and services

Dr. Reddys at a glance 7/6/2017 8

Our products are
developed at our R&D
centres in different
regions of the world
R&D

Research and development sites

UK - Chirotech Netherlands - Octoplus

Technology Technology Development
Development Centre, Leiden
Centre, Cambridge

USA - India - Integrated

Development centre, Product Development
Princeton, NJ Centre, Hyderabad

Dr. Reddys at a glance 7/6/2017 9

We strive to be the first to
launch tough-to-make
products and
differentiated
formulations
IP and technology-driven active ingredients

Complex generics and biologics

Differentiated formulations and novel products for

unmet needs

Dr. Reddys at a glance 7/6/2017 10

We have introduced
services aimed at
improving patient
outcomes or partner
needs

Innovative Helping Value added

services doctors & service
around our pharmacists offerings
products create better
outcomes API and pure
Proprietary generics
Products Branded generics

Dr. Reddys at a glance 7/6/2017 11

We are
known for
our R&D
strengths...

Advanced technology

Globalized R&D

External R&D relationships

Dr. Reddys at a glance 7/6/2017 12

...and our
people
practices

We were ranked first among

biotech and pharmaceutical
companies in India by Great Place
to work in its Best Companies
to Work For survey, 2013

Best
Companies
to work for

Dr. Reddys at a glance 7/6/2017 13

We are
recognized for
our strong
corporate
governance
Our Board was named one of
Indias best managed
boards by Mint and Aon
Hewitt and by Economic Times
and Hays in their respective
studies

We were declared Indian

MNC of the year at the All
India Management Association Indias
Best
(AIMA) Awards 2016.

In the Asian Centre for

Corporate Governance & Managed
Sustainabilitys Leadership,
Corporate Governance, Board
Sustainability & CSR Awards
2015, we were conferred with
the "Best Governed
Company" award. Dr. Reddys at a glance 7/6/2017 14
A strong
presence in Europe

highly 6%

regulated PSAI and

markets Proprietary
15%
Revenue distribution North
and geographical mix America

Emerging $2.2 BN 47%

Markets FY 2017
15%

India
17%

Slide library 7/6/2017 15

Section 2

Our journey
so far
Charting out a course in unknown waters and learning along the way
has made the difference to us.

- Satish Reddy, Chairman

Our journey has covered six phases

198490 199095 19952000 2000-2005 2005-2010 2010 onwards

Establishing a Moving from an Creating world- Building an Globalizing and Pursuing
viable business entrepreneurial class capabilities institution growing inorganically excellence
to a professional
organization

Dr. Reddys at a glance 7/6/2017 17

From an API
manufacturer
we have
grown into
a global
pharmaceutical
firm

Dr. Reddys at a glance 7/6/2017 18

We have
moved from
an
entrepreneur-
led firm to a
professional
meritocracy

Dr. Reddys at a glance 7/6/2017 19

From 1995
onwards,
we focused
on creating
world class
capabilities

Regulatory,
IP, Quality,
Manufactur
ing, Legal,
SH&E

Dr. Reddys at a glance 7/6/2017 20

In the early
2000s, we
focused on
institution
building

Dr. Reddys at a glance 7/6/2017 21

Multiple
acquisitions
and business
development
deals have
fuelled non -
linear growth

Dr. Reddys at a glance 7/6/2017 22

Section 3

An exciting future

We are impacting millions of patients by empowering our people to act with agility and to do what
is tough and worthwhile.

- G V Prasad, CEO
We are aiming high

Become one of the leading global generics companies

providing tough-to-make and truly differentiated products that meet
patients unmet needs

Bring affordable biosimilars to patients in developed and

developing markets by:

Enhancing regulatory skills

Establishing the organization and skills for a full powered biosimilars

entity

Launch differentiated proprietary products for patients in the USA

Dr. Reddys at a glance 7/6/2017 24

We consistently apply lessons we have learned in our
journey so far

Doing the right thing Define success in Unleash the potential

for your customers, terms of of your people by
Your rate of growth is
partners, society and purpose rather elevating their
limited only by your
other stakeholders than just aspirations and
imagination and the
leads to enduring financial metrics helping them
leaders you have
success achieve them

Dr. Reddys at a glance 7/6/2017 25

The best way to
predict your future
is to create it
- Abraham Lincoln

Dr. Reddys at a glance 7/6/2017 26

Contact.
Investor relations Media relations
Saunak Savla Calvin Printer
saunaks@drreddys.com calvinprinter@drreddys.Com
(Ph: +91-40-49002135) (Ph: +91-40- 49002121)

About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products Dr. Reddys offers a portfolio of products and services including APIs, custom pharmaceutical services,
generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddys operates in markets across
the globe. Our major markets include USA, India, Russia and other CIS countries. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the managements current views and assumptions and involve known or unknown risks and
uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words
"may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events
may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels
and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central
banks and/or governments, (v) the impact of acquisitions or reorganisation , including related integration issues.

The company assumes no obligation to update any information contained herein.

Registered Office: Dr. Reddys Laboratories Ltd. 8-2-337 | Road No. 3, Banjara Hills, Hyderabad - 500034, Telangana, India.
Tel: 91 40 4900 2900 | Fax: 91 40 4900 2999 | Web: www.drreddys.com